Journals / Medicine Science / 2016 / Cilt: 5 - Sayı: 2

Endocannabinoid Systetm: Neuropharmacological Implications

Pages
562–582
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In present work cannabinoids are presented as a viable therapeutic target in CNS disorders that include Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, epilepsy, Parkinson's and Huntington's disease.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Marijuana or cannabis has been part of humanity's medicine chest for almost as long as history has been recorded.
📊
Key Findings & Data:Cannabinoids are a class of diverse chemical compounds isolated from cannabis that act on cannabinoid receptors (CB1 & CB2).
💡
Conclusion & Impact:In present work cannabinoids are presented as a viable therapeutic target in CNS disorders that include Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, epilepsy, Parkinson's and Huntington's disease.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Marijuana or cannabis has been part of humanity's medicine chest for almost as long as history has been recorded. Cannabinoids are a class of diverse chemical compounds isolated from cannabis that act on cannabinoid receptors (CB1 & CB2). The ligands for these receptor proteins include the endocannabinoids (produced naturally in the body by humans and animals), the phytocannabinoids (found in cannabis and some other plants) and synthetic cannabinoids (manufactured artificially). The endogenous cannabinoid system, named after the plant that led to its discovery, is perhaps the most important physiologic system involved in establishing and maintaining human health. The human body's neurological, circulatory, endocrine, digestive and musculoskeletal systems have now all been shown to possess cannabinoid receptor sites. Indeed, even cartilage tissue has cannabinoid receptors, which makes cannabis a prime therapeutic agent to treat various complicated ailments. In each tissue, the cannabinoid system performs different tasks, but the goal is always the same: homeostasis, the maintenance of a stable internal environment despite fluctuations in the external environment. The endocannabinoid system, with its presence in almost all organs especially in CNS makes it a bridge between body and mind. By understanding this system we begin to see a mechanism that explains how states of consciousness can promote health and sense of well being. Nausea, vomiting, stimulation of appetite, symptomatic relief of cancer pain and/or management of neuropathic pain, stroke, cancer, drug dependence, glaucoma, autoimmune uveitis, osteoporosis, sepsis, hepatic, renal, intestinal and cardiovascular disorders are the various diverse areas where cannabinoids have shown their therapeutic presence and potential. In present work cannabinoids are presented as a viable therapeutic target in CNS disorders that include Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, epilepsy, Parkinson's and Huntington's disease.

🔖

Cite This Article

SHARMA, V. K., CHANDEL, A., ACHARYA, G., DESHMUKH, R. (2016). Endocannabinoid Systetm: Neuropharmacological Implications. Medicine Science, Cilt: 5 - Sayı: 2, 562–582. https://ajindex.com/articles/277536

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Amar MB. Pschodysleptic Drugs: Cannabis and Hallucinogens, University of Montreal, 2001 2. Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev. 2006
  2. 58(3):389--462. 3. Li HL. An archeological and historical account of cannabis in China. Econ Bot. 1974
  3. Aggarwal SK, Carter GT, Sullivan MD, ZumBrunnen C, Morrill R, Mayer JD. Medicinal use of cannabis in the United States: historical perspectives, current trends, and future directions. Opioid Manag. 2009
  4. 5(3):153--68. 5. Wood TB, Spivey WTN, Easterfield TH. Charas, the resin of Indian hemp. Chem Soc. 1896
  5. 46 6. Th. Geschwinde, Rauschdrogen: Marktformen und Wirkungsweisen, 3rd edition, Springer Verlag, Berlin, 1996. 7. Grotenhermen F, Muller--Vahl K. The therapeutic potential of cannabis and cannabinoids. Dtsch Arztebl Int. 2012
  6. 109(29--30):495--501. 8. Grotenhermen F. Cannabinoids and the Endocannabinoid System. Cannabinoids. 2006
  7. 1(1):10--4. 9. Marzo DV, Melck D, Bisogno T, De Petrocellis L. Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci. l998
  8. 2l(l2):52l--8. 10. Devane WA, Dysarz FA 3rd, Johnson MR, Melvin LS, Howlett AC. Determination and characterization of cannabinoid receptor in rat brain. Mol Pharmacol. 1988
  9. 34(5):605-13. ll.Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner Tl. Structure of cannabinoid receptor and functional expression of the cloned cDNA. Nature. l990
  10. 346(6284):561--4. l2. Munro S, Thomas KL, Abu--Shaar M. Molecular characterization of peripheral receptor for cannabinoids. Nature. l993
  11. 365(644l):6l-5. l3.Begg M, Pacher P, Batkai S, Hyiaman OD, Offertaler L, MoFM, Liu J, Kunos G. Evidence for novel cannabinoid receptors. Pharmacol Ther. 2005
  12. 106(2):l33--45. l4. Gomez--Ruiz M, Hernandez M, de Miguel R, Ramos JA. An overview on the biochemistry of the cannabinoid system. Mol Neurobiol. 2007
  13. 36(l):3--14. 15.Wilson RI, Nicoll RA. Endocannabinoid signaling in the brain. Science. 2002
  14. 296(5568):678--82. 16. Silvestri C, Marzo DV. The endocannabinoid system in energy homeostasis and the etiopathology of metabolic disorders. Cell Metab. 2013
  15. l7(4):475 --90. 17. Tucci SA, Halford C, Harrold A, Kirkham TC. Therapeutic potential of targeting the endocannabinoids: implications for the treatment of obesity, metabolic syndrome, drug abuse and smoking cessation. Curr Med Chem. 2006
  16. l3(22):2669--80. 18. Ruiz JF, Berrendero F, Hernandez ML, Ramos JA. The endo